{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=AMG+420&page=2",
    "query": {
      "intervention": "AMG 420",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=AMG+420&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-21T13:09:04.451Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02729025",
      "title": "Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflammation in Patients With Elevated Lipoprotein(a) (Lp(a))",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Subjects With Hyperlipidemia, Dyslipidemia"
      ],
      "interventions": [
        {
          "name": "Evolocumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "50 Years to 80 Years"
      },
      "enrollment_count": 129,
      "start_date": "2016-04-14",
      "completion_date": "2018-04-05",
      "has_results": true,
      "last_update_posted_date": "2022-09-23",
      "last_synced_at": "2026-09-21T13:09:04.451Z",
      "location_count": 5,
      "location_summary": "Miami, Florida • Las Vegas, Nevada • Mooresville, North Carolina + 2 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "Mooresville",
          "state": "North Carolina"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Hurst",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02729025"
    },
    {
      "nct_id": "NCT02624869",
      "title": "Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Children With Inherited Elevated Low-density Lipoprotein Cholesterol (Familial Hypercholesterolemia)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Familial Hypercholesterolemia"
      ],
      "interventions": [
        {
          "name": "Evolocumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "10 Years to 17 Years"
      },
      "enrollment_count": 163,
      "start_date": "2016-09-10",
      "completion_date": "2021-06-01",
      "has_results": true,
      "last_update_posted_date": "2024-05-29",
      "last_synced_at": "2026-09-21T13:09:04.451Z",
      "location_count": 3,
      "location_summary": "The Bronx, New York • Cincinnati, Ohio • Nashville, Tennessee",
      "locations": [
        {
          "city": "The Bronx",
          "state": "New York"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02624869"
    },
    {
      "nct_id": "NCT01879319",
      "title": "Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a Prefilled Autoinjector/Pen",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Primary Hypercholesterolemia",
        "Mixed Dyslipidemia"
      ],
      "interventions": [
        {
          "name": "Evolocumab AMD",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Evolocumab AI/pen",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 164,
      "start_date": "2013-07-11",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2022-11-30",
      "last_synced_at": "2026-09-21T13:09:04.451Z",
      "location_count": 22,
      "location_summary": "Phoenix, Arizona • Encino, California • Thousand Oaks, California + 18 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Thousand Oaks",
          "state": "California"
        },
        {
          "city": "Tustin",
          "state": "California"
        },
        {
          "city": "Ventura",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01879319"
    },
    {
      "nct_id": "NCT02739984",
      "title": "Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hypercholesterolemia",
        "Mixed Dyslipidemia",
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Evolocumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo to Evolocumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 424,
      "start_date": "2016-05-17",
      "completion_date": "2017-08-03",
      "has_results": true,
      "last_update_posted_date": "2018-08-31",
      "last_synced_at": "2026-09-21T13:09:04.451Z",
      "location_count": 46,
      "location_summary": "Tuscumbia, Alabama • Phoenix, Arizona • Lomita, California + 39 more",
      "locations": [
        {
          "city": "Tuscumbia",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Lomita",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Roseville",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02739984"
    },
    {
      "nct_id": "NCT03156023",
      "title": "Multiple Ascending Doses of Rozibafusp Alfa (AMG 570) in Adults With Rheumatoid Arthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Rozibafusp Alfa",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 34,
      "start_date": "2017-08-14",
      "completion_date": "2020-06-12",
      "has_results": true,
      "last_update_posted_date": "2024-05-14",
      "last_synced_at": "2026-09-21T13:09:04.451Z",
      "location_count": 3,
      "location_summary": "Anniston, Alabama • Duncansville, Pennsylvania • Dallas, Texas",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Duncansville",
          "state": "Pennsylvania"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03156023"
    },
    {
      "nct_id": "NCT02392559",
      "title": "Trial Assessing Efficacy, Safety and Tolerability of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition in Paediatric Subjects With Genetic Low-Density Lipoprotein (LDL) Disorders",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Heterozygous Familial Hypercholesterolemia"
      ],
      "interventions": [
        {
          "name": "Evolocumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "10 Years to 17 Years"
      },
      "enrollment_count": 158,
      "start_date": "2016-03-24",
      "completion_date": "2019-11-25",
      "has_results": true,
      "last_update_posted_date": "2022-11-08",
      "last_synced_at": "2026-09-21T13:09:04.451Z",
      "location_count": 12,
      "location_summary": "Farmington, Connecticut • Wilmington, Delaware • Iowa City, Iowa + 9 more",
      "locations": [
        {
          "city": "Farmington",
          "state": "Connecticut"
        },
        {
          "city": "Wilmington",
          "state": "Delaware"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Towson",
          "state": "Maryland"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02392559"
    },
    {
      "nct_id": "NCT01854918",
      "title": "Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed Dyslipidemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hyperlipidemia and Mixed Dyslipidemia"
      ],
      "interventions": [
        {
          "name": "Evolocumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Standard of Care",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 3681,
      "start_date": "2013-04-23",
      "completion_date": "2018-05-31",
      "has_results": true,
      "last_update_posted_date": "2019-06-11",
      "last_synced_at": "2026-09-21T13:09:04.451Z",
      "location_count": 107,
      "location_summary": "Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 94 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01854918"
    },
    {
      "nct_id": "NCT02867813",
      "title": "Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Dyslipidemia"
      ],
      "interventions": [
        {
          "name": "Evolocumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "40 Years to 85 Years"
      },
      "enrollment_count": 5035,
      "start_date": "2016-09-02",
      "completion_date": "2022-03-21",
      "has_results": true,
      "last_update_posted_date": "2023-04-07",
      "last_synced_at": "2026-09-21T13:09:04.451Z",
      "location_count": 144,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 136 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Banning",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02867813"
    },
    {
      "nct_id": "NCT01516879",
      "title": "Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hypercholesterolemia"
      ],
      "interventions": [
        {
          "name": "Evolocumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Atorvastatin",
          "type": "DRUG"
        },
        {
          "name": "Ezetimibe",
          "type": "DRUG"
        },
        {
          "name": "Diet Only",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 905,
      "start_date": "2012-01-05",
      "completion_date": "2013-10-14",
      "has_results": true,
      "last_update_posted_date": "2022-07-22",
      "last_synced_at": "2026-09-21T13:09:04.451Z",
      "location_count": 41,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 33 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "Spring Valley",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01516879"
    },
    {
      "nct_id": "NCT01042379",
      "title": "I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Neoplasms",
        "Breast Cancer",
        "Breast Tumors",
        "Angiosarcoma",
        "TNBC - Triple-Negative Breast Cancer",
        "HER2-positive Breast Cancer",
        "HER2-negative Breast Cancer",
        "Hormone Receptor Positive Tumor",
        "Hormone Receptor Negative Tumor",
        "Early-stage Breast Cancer",
        "Locally Advanced Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Standard Therapy",
          "type": "DRUG"
        },
        {
          "name": "AMG 386 with or without Trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "AMG 479 (Ganitumab) plus Metformin",
          "type": "DRUG"
        },
        {
          "name": "MK-2206 with or without Trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "AMG 386 and Trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "T-DM1 and Pertuzumab",
          "type": "DRUG"
        },
        {
          "name": "Pertuzumab and Trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "Ganetespib",
          "type": "DRUG"
        },
        {
          "name": "ABT-888",
          "type": "DRUG"
        },
        {
          "name": "Neratinib",
          "type": "DRUG"
        },
        {
          "name": "PLX3397",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab - 4 cycle",
          "type": "DRUG"
        },
        {
          "name": "Talazoparib plus Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "Patritumab and Trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab - 8 cycle",
          "type": "DRUG"
        },
        {
          "name": "SGN-LIV1A",
          "type": "DRUG"
        },
        {
          "name": "Durvalumab plus Olaparib",
          "type": "DRUG"
        },
        {
          "name": "SD-101 + Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Tucatinib plus trastuzumab and pertuzumab",
          "type": "DRUG"
        },
        {
          "name": "Cemiplimab",
          "type": "DRUG"
        },
        {
          "name": "Cemiplimab plus REGN3767",
          "type": "DRUG"
        },
        {
          "name": "Trilaciclib with or without trastuzumab + pertuzumab",
          "type": "DRUG"
        },
        {
          "name": "SYD985 ([vic-]trastuzumab duocarmazine)",
          "type": "DRUG"
        },
        {
          "name": "Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "Amcenestrant",
          "type": "DRUG"
        },
        {
          "name": "Amcenestrant + Abemaciclib",
          "type": "DRUG"
        },
        {
          "name": "Amcenestrant + Letrozole",
          "type": "DRUG"
        },
        {
          "name": "ARX788",
          "type": "DRUG"
        },
        {
          "name": "ARX788 + Cemiplimab",
          "type": "DRUG"
        },
        {
          "name": "VV1 + Cemiplimab",
          "type": "DRUG"
        },
        {
          "name": "Datopotamab deruxtecan",
          "type": "DRUG"
        },
        {
          "name": "Datopotamab deruxtecan + Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Zanidatamab",
          "type": "DRUG"
        },
        {
          "name": "Lasofoxifene",
          "type": "DRUG"
        },
        {
          "name": "Z-endoxifen",
          "type": "DRUG"
        },
        {
          "name": "ARV-471",
          "type": "DRUG"
        },
        {
          "name": "ARV-471 + Letrozole",
          "type": "DRUG"
        },
        {
          "name": "ARV-471 + Abemaciclib",
          "type": "DRUG"
        },
        {
          "name": "Endoxifen + Abemaciclib",
          "type": "DRUG"
        },
        {
          "name": "Rilvegostomig + TDXd",
          "type": "DRUG"
        },
        {
          "name": "Dan222 + Niraparib",
          "type": "DRUG"
        },
        {
          "name": "Sarilumab + Cemiplimab + Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "GSK 5733584",
          "type": "DRUG"
        },
        {
          "name": "GSK 5733584 + Dostarlimab",
          "type": "DRUG"
        },
        {
          "name": "Ivonescimab (20mg/kg Q3W)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "QuantumLeap Healthcare Collaborative",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5000,
      "start_date": "2010-03-01",
      "completion_date": "2031-12",
      "has_results": false,
      "last_update_posted_date": "2026-05-06",
      "last_synced_at": "2026-09-21T13:09:04.451Z",
      "location_count": 42,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 36 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Davis",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01042379"
    }
  ]
}